Code Ready

Level 1 of 6Core

Opioid and sedative poisoning

The core to-do list — diagnose and manage, at a glance

Diagnose— recognise it

  • Look for the triad: depressed consciousness, respiratory depression and miosis in a patient with dry skin — that is opioid poisoning until proved otherwise. Take the history for the agent and the route — heroin or an unknown illicit supply (now dominated by high-potency synthetic fentanyl analogues), prescribed opioids (methadone, modified-release oxycodone, transdermal patches), benzodiazepines, z-drugs, barbiturates, GHB or ethanol — and assume a mixed ingestion until levels return.
  • Count the respiratory rate yourself for a full 60 seconds: a rate below 12 is abnormal, below 10 is typical of significant opioid overdose, and depth matters as much as rate — shallow breathing at 14 per minute may ventilate less than slow deep breathing at 8 — while snoring or gurgling indicates superimposed airway obstruction. Record the GCS broken into eye, motor and verbal components, with an explicit judgement of whether the patient protects their own airway: can they swallow their saliva, and do they gag on suction? Measure the pupils in millimetres, not as pinpoint.
  • Check the capillary blood glucose within minutes in every case — hypoglycaemia is both a mimic and a frequent accompaniment, and unless promptly treated severe hypoglycaemia can cause irreversible brain damage. Take an arterial or venous blood gas — it is the single most important test, because pulse oximetry never measures ventilation: pH below 7.30 with a rising PaCO2 above about 6.5 kPa (50 mmHg) in a sedated patient is a decision, not a data point, and an added lactic acidosis suggests hypoxia, seizure or shock. A normal saturation on supplemental oxygen is profoundly misleading: oxygen corrects the saturation while carbon dioxide continues to rise.Not available at your setup — Arterial blood gas.
  • Undress the patient completely and search the whole body surface — including the back and beneath dressings — for needle track marks, injection-site abscesses, pressure injury and transdermal opioid patches. Look also for bradycardia, hypotension and hypothermia (a hypothermic patient may have a barely perceptible pulse and blood pressure), dry skin, absent bowel sounds and urinary retention.
  • Do not let an atypical picture put you off: pupils may be normal or dilated with pethidine, tramadol, propoxyphene and diphenoxylate, with a co-ingested stimulant or anticholinergic, or with established hypoxia — miosis marks exposure, not severity, and is abolished by profound hypoxia. Tramadol and pethidine are proconvulsant — above about 1 g/day of pethidine, norpethidine accumulation produces seizures that are not reversible with naloxone — and methadone prolongs the QT interval and can cause torsades de pointes. Sedative poisoning gives a less profound but similar picture: disinhibition, ataxia, dysarthria, nystagmus and delirium precede coma; barbiturates add profound hypotension, bullous lesions over pressure areas and loss of brainstem reflexes deep enough to mimic brain death; GHB gives very deep coma with abrupt spontaneous awakening within hours.
  • Recognise the features of immediate risk of death: respiratory rate below 8–10 per minute, apnoeic pauses or agonal breathing; SpO2 below 90% despite supplemental oxygen; GCS 8 or less or an absent gag reflex; a rising PaCO2 with a falling pH; hypotension unresponsive to fluid; core temperature below 35°C; seizure, arrhythmia, a QRS above 100–120 ms or a prolonged QTc; no response to a cumulative 10 mg of naloxone; aspiration or persistent hypoxaemia after reversal; a long-acting or modified-release preparation, a transdermal patch or a body packer; and any child requiring naloxone at all. Severity at presentation does not predict severity at four hours — asymptomatic or mildly symptomatic patients are observed for at least 4–6 hours.

Manage now— do this, in order

  • Ventilation is the treatment; the antidote is a convenience — protection of the airway and assisted ventilation are the most important treatment measures for any poisoned patient, and they precede the antidote. Establish a patent airway by positioning, suction and insertion of a nasopharyngeal or oropharyngeal airway, and nurse the unintubated patient in the lateral (recovery) position with suction available.
  • Assist with a bag-valve-mask device or mechanical ventilator: assisted ventilation at 10–12 breaths per minute in an adult is the single highest-value intervention here — support the airway, ventilate, give naloxone and re-decide at three minutes. Intubate if the patient is deeply comatose or airway reflexes are depressed — but these airway interventions may not be necessary if the patient is intoxicated by an opioid and responds to intravenous naloxone.Doctor / NurseNot available at your setup — Mechanical ventilator, Endotracheal intubation kit. Where no ventilator is available, ventilate by bag-valve-mask at 10–12 breaths per minute while naloxone takes effect.
  • Naloxone, adult, illicit or unknown opioid, apnoeic or barely breathing: 0.4–2 mg intravenously, or the same dose intramuscularly or by endotracheal tube, or 2–4 mg by intranasal spray; repeat every 2–3 minutes, escalating — up to 5–10 mg may be required for potent opioids, and total doses of 10 mg or greater may be needed for fentanyl or buprenorphine. Adult breathing but inadequately: 0.4 mg intravenously repeated every 2–3 minutes, titrated (chart).Doctor / Nurse
  • Naloxone in prescribed-opioid, palliative or post-operative over-sedation or a known chronic user: a tester dose of 0.04 mg intravenously, taken from naloxone 0.4 mg diluted to 10 mL with 0.9% sodium chloride (0.04 mg/mL), repeated every 1–2 minutes and titrated to respiratory rate — this reverses respiratory depression without entirely reversing analgesia. Child: 0.01 mg/kg intravenously, intramuscularly or intraosseously; if inadequate, 0.1 mg/kg (usual maximum 2 mg per dose), repeated as needed. Never give naloxone to the neonate of an opioid-using or opioid-treated mother — it may precipitate severe withdrawal and seizures; support the airway and ventilate instead. Where re-sedation is expected, give repeated boluses at the effective dose, or a continuous infusion at approximately two-thirds of the effective bolus dose per hour, titrated hourly against the respiratory rate.Doctor / NurseNot available at your setup — Infusion pump.
  • The endpoint is a respiratory rate of about 12 or more with adequate depth, a maintained saturation without assistance, and return of airway-protective reflexes — not a fully alert patient; a rousable but drowsy patient who is breathing well and swallowing their own saliva is a success. Never titrate the antidote to consciousness — titrate to respiration, because over-reversal produces acute withdrawal with agitation, vomiting into an unprotected airway, aspiration, and a patient who self-discharges into the circumstances that nearly killed them. Never keep escalating past a cumulative 10 mg with no respiratory response — failure to respond to 10 mg is information, not a reason for more naloxone: consider a non-opioid cause, a mixed overdose, hypoxic brain injury, a structural intracranial cause, or buprenorphine, and ventilate.
  • Remove every transdermal opioid patch and wash the skin beneath it — a patch left in place keeps releasing drug for hours after the naloxone has worn off, and re-sedation after the antidote wears off is the commonest mechanism of a death occurring after apparently successful treatment.
  • Give 50% dextrose 50–100 mL by intravenous bolus to all obtunded, comatose or convulsing patients unless a rapid point-of-care glucose test rules out hypoglycaemia; in children 10% dextrose 2–5 mL/kg intravenously. Thiamine 100 mg intramuscularly before the dextrose, or in the intravenous fluids, in patients with alcohol use disorder or malnourishment who may have marginal thiamine stores.Doctor / Nurse
  • Hypotension: repeated 200 mL intravenous boluses of 0.9% sodium chloride or other isotonic crystalloid up to a total of 1–2 litres (paediatric 10–20 mL/kg per bolus); if fluid therapy is unsuccessful after adequate volume replacement, give vasopressors by intravenous infusion — noradrenaline first; and remember hypothermia may itself be the cause of refractory hypotension, so rewarm gradually unless the patient is in cardiac arrest. Seizures: lorazepam 2–3 mg intravenously, or diazepam 5–10 mg intravenously, or midazolam 5–10 mg intramuscularly if intravenous access is not immediately available (paediatric lorazepam 0.1 mg/kg to a maximum 4 mg, diazepam 0.1–0.3 mg/kg to a maximum 10 mg, or midazolam 0.1 mg/kg IV or 0.2 mg/kg buccally); if convulsions continue, phenobarbital 15–20 mg/kg slowly intravenously over no less than 30 minutes — for drug-induced seizures phenobarbital is the preferred agent. A wide QRS from co-ingested sodium-channel blockade: sodium bicarbonate 50–100 mEq by intravenous bolus. Torsades de pointes: magnesium 2 g intravenously over 2 minutes.Doctor / Nurse
  • Activated charcoal for small or moderate ingestions: 50–100 g orally or by gastric tube as an aqueous slurry in an adult, 1 g/kg (maximum 50 g) in a child — but not to a comatose or convulsing patient unless the airway is first protected by a cuffed endotracheal tube, and never at the cost of delaying ventilation or naloxone; whole-bowel irrigation with polyethylene glycol (adult 1–2 L/hour, child 25 mL/kg/hour) is indicated for body packers and large modified-release ingestions. Continuous observation for at least 3–4 hours after the last naloxone dose is mandatory; some authorities specify at least 6 hours, and the longer figure is safer — and features of opioid poisoning can be prolonged for up to 48 hours after methadone or oxycodone, so those agents, with modified-release morphine, transdermal fentanyl and buprenorphine, warrant at least 24 hours of monitored observation. Flumazenil should rarely be given, and the safe management of sedative poisoning is airway, oxygen, assisted ventilation, fluids, warmth and time.
NaloxoneDoseRepeat / escalation
Adult, illicit or unknown opioid, apnoeic0.4–2 mg IV (same dose IM or by ETT; 2–4 mg intranasal)Every 2–3 min; up to 5–10 mg for potent opioids; ≥10 mg for fentanyl or buprenorphine
Adult, breathing but inadequately0.4 mg IVEvery 2–3 min, titrated
Prescribed opioid / chronic userTester 0.04 mg IV (0.4 mg diluted to 10 mL = 0.04 mg/mL)Every 1–2 min, titrated to respiratory rate
Child0.01 mg/kg IV, IM or IO; if inadequate 0.1 mg/kgUsual maximum 2 mg per dose, repeated as needed
Maintenance (re-sedation expected)Infusion at ~two-thirds of the effective bolus dose per hourTitrated hourly against respiratory rate

Refer / escalate

Escalate or transfer for a respiratory rate below 8–10 with apnoeic pauses or agonal breathing, SpO2 below 90% on oxygen, GCS 8 or less or an absent gag reflex, a rising PaCO2 with a falling pH, hypotension unresponsive to fluid, core temperature below 35°C, seizure, arrhythmia, QRS above 100–120 ms or prolonged QTc, no response to a cumulative 10 mg of naloxone, aspiration or persistent hypoxaemia after reversal, a long-acting or modified-release preparation, a transdermal patch, a body packer — and for any child requiring naloxone at all.

Read the full lesson free

Create a free account to unlock every page, the level exams, and progress tracking.

Sign up freeLog in